Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma.

ABSTRACT:

Objective

A subset of meningiomas recur after surgery and radiation therapy, but no medical therapy for recurrent meningioma has proven effective.

Methods

Pasireotide LAR is a long-acting somatostatin analog that may inhibit meningioma growth. This was a phase II trial in patients with histologically confirmed recurrent or progressive meningioma designed to evaluate whether pasireotide LAR prolongs progression-free survival at 6 months (PFS6). Patients were stratified by histology (atypical [World Health Organization grade 2] and malignant [grade 3] meningiomas in cohort A and benign [grade 3] in cohort B).

Results

Eighteen patients were accrued in cohort A and 16 in cohort B. Cohort A had median age 59 years, median Karnofsky performance status 80, 17 (94%) had previ

SUBMITTER: Norden AD 

PROVIDER: S-EPMC4335993 | biostudies-literature | 2015 Jan

REPOSITORIES: biostudies-literature